 | Up a level |
Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2012). CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2013). Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445